Primary aldosteronism

Clinical Laboratory

Volumn 48, Issue 3-4, 2002, Pages 181-190

  Fardella, Carlos E ^a   Mosso, Lorena ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Aldosterone renin ratio; Hypertension; Mineralocorticoids; Primary aldosteronism

Indexed keywords

ALDOSTERONE; AMILORIDE; ANTIHYPERTENSIVE AGENT; CARBENOXOLONE; CORTICOTROPIN; DEXAMETHASONE; GLYCYRRHIZA EXTRACT; HYDROCORTISONE; MINERALOCORTICOID; NIFEDIPINE; PREDNISONE; RENIN; SPIRONOLACTONE; TRIAMTERENE;

ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL HYPERPLASIA; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ERECTILE DYSFUNCTION; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; LIBIDO; MENSTRUATION DISORDER; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; REVIEW; SCREENING TEST;

ALDOSTERONE; CLINICAL CHEMISTRY TESTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERALDOSTERONISM; PREVALENCE;

GLYCYRRHIZA;

EID: 0036203230     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Primary aldosteronism
2. Cellular origin of aldosteronomas
3. Correctable subsets of primary aldosteronism: Primary adrenal hyperplasia and renin responsive adenoma
4. Primary aldosteronism. Review article
5. Primary adrenal hyperplasia: A new subset of primary aldosteronism
6. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone
7. A chimeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension
8. Isolated clinical syndrome of primary aldosteronism in four patients with adrenocortical carcinoma
9. Normokalemic primary aldosteronism. A detectable cause of curable "essential" hypertension
10. Frequency of surgical treatment for hypertension in adults at the Mayo Clinic from 1973 to 1975
11. Diagnosis and treatment of primary hyperaldosteronism
12. Inappropriate elevation of the aldosterone/plasma renin activity ratio in hypertensive patients with increases of 11-deoxycorticosterone and 18-hydroxy-11-deoxycorticosterone: A subtype of essential hypertension?
13. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers
14. Primary hyperaldosteronism: A missed diagnosis in "essential hypertensives"?
15. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients
16. Primary aldosteronism: Issues in diagnosis and management
17. High incidence of primary aldosteronism in 199 patients referred with hypertension
18. Primary hyperaldosteronism in essential hypertensives: Prevalence, biochemical profile, and molecular biology
19. High prevalence of primary aldosteronism in the Tayside hypertension clinic population
20. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore
21. Clinical characteristics of primary aldosteronism: Its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital
22. Prevalence of primary aldosteronism in unselected hypertensive populations. Screening and definitive diagnosis
23. Cautions over the current epidemic of primary aldosteronism
24. Cautions over idiopathic aldosteronism
25. The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex
26. Cloning and expression of a cDNA for human cytochrome P450aldo as related to primary aldosteronism
27. Aldosterone synthase cytochrome P450 expressed in the adrenals of patients with primary aldosteronism
28. Role of steroid 11β-hydroxylase and 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans
29. Characterization of two genes encoding human steroid 11β-hydroxylase (P45011β)
30. Control of plasma aldosterone in primary aldosteronism: Distinction between adenoma and hyperplasia
31. Primary aldosteronism. Part I Diagnosis of primary hyperaldosteronism
32. Primary aldosteronism. Part II Differential diagnosis of primary hyperaldosteronism and pseudoaldosteronism
33. Identification and implications of new subtypes of mineralocorticoid hypertension
34. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossover between CYP11B1 and CYP11B2
35. Dexamethasone-suppressible hyperaldosteronism
36. Isolation and identification of 18-hydroxycortisol from the urine of patients with primary aldosteronism
37. Biosynthesis of 18-oxocortisol by aldosterone-producing adrenal tissue
38. Elevated urinary excretion of 18-oxocortisol in glucocorticoid-remediable aldosteronism
39. Defective fasciculata zone function as the mechanism of glucocorticoid-remediable aldosteronism
40. Transient fall and subsequent return of high aldosterone secretion by adrenal adenoma during continued dexamethasone administration
41. ACTH-dependent aldosterone excess due to adrenocortical adenoma: A variant of primary aldosteronism
42. Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasmas: Correlation with P450scc expression
43. The role of ACTH in the episodic release of aldosterone in patients with idiopathic adrenal hyperplasia, hypertension, and hyperaldosteronism
44. Circadian rhythm and effect of posture on plasma aldosterone in primary aldosteronism
45. Influence of sodium intake on the reliability of active renin as a measure of the renin-angiotensin system in essential hypertension
46. Excess of mineralocorticoids in essential hypertension: Clinical-diagnostic approach
47. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism
48. Measurement of low levels of plasma renin activity. A methodological improvement
49. Fludrocortisone suppression test
50. Hyperaldosteronism
51. Primary aldosteronism
52. Studies of the control of plasma aldosterone concentration in normal man. I. Response to posture, acute and chronic volume depletion, and sodium loading
53. The plasma aldosterone response to angiotensin II infusion in aldosterone-producing adenoma and idiophatic hyperaldosteronism
54. Steroids and hypertension
55. Glucocorticoid-remediable aldosteronism (GRA): Diagnosis, variability of phenotype and regulation of potassium homeostasis
56. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism
57. Diagnosis of glucocorticoid -remediable aldosteronism in primary aldosteronism: Aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene
58. Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene
59. The unique steroidogenesis of the aldosteronoma in the differential diagnosis of primary aldosteronism
60. Plasma 18-oxocortisol levels in patients with adrenocortical disorders
61. Serum 18-hydroxycortisol in primary aldosteronism, hypertension and normotensives
62. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension
63. The adrenals
64. Imaging in endocrinology: The adrenal gland
65. Adrenal macrotumors diagnosed by computed tomography
66. Predictive value of preoperative test in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma
67. Localization of functional adrenal tumors by computed tomography and venous sampling
68. Primary aldosteronism: Adrenal venous sampling
69. The dexamethasone-modified adrenal scintiscan in hyporeninemic aldosteronism (tumor versus hyperplasia): A comparison with adrenal venography and adrenal venous aldosterone
70. Molecular biology of mineralocorticoid metabolism
71. Mineralocorticoid hypertension
72. Hypertension and mineralocorticoids. Usefulness of renin and aldosterone measurements
73. Inherited forms of mineralocorticoid hypertension
74. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle
75. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess
76. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase
77. Localization of 11β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor
78. Mineralocorticoid activity of carbenoxolone: Contrasting effects of carbenoxolone and liquorice on 11β-hydroxysteroid dehydrogenase activity in man
79. Persistent hypokalemia after successful adrenalectomy in a patient with Cushing's syndrome due to ectopic ACTH secretion: Possible role of 11β-hydroxysteroid dehydrogenase
80. Cloning of human mineralocorticoid receptor DNA: Structural and functional kinship with the glucocorticoid receptor
81. Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands
82. A genetic defect resulting in mild low-renin hypertension
83. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene
84. Liddle's syndrome: Heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel
85. A de novo missense mutation of the β-subunit of the ephitelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity
86. Liddle's disease caused by a missense mutation of beta subunit of the ephitelial sodium channel gene
87. Genotype-phenotype analysis of a new family with Liddle's syndrome
88. Amiloride-sensitive epithelial Na channel is made of three homologous subunits
89. + channel
90. Liddle's syndrome revisited: A disorder of sodium reabsorption in the distal tubule
91. Disorders of steroid 11β-hydroxylase isozymes
92. A mutation in CYP11B1 (Arg448→His) associated with steroid 11β-hydroxylase deficiency in Jews of Moroccan origin
93. 17α-Hydroxylase/17,20 lyase deficiency:from clinical investigation to molecular definition
94. Deletion of amino acids Asp487-Ser488-Phe489 in human cytochrome P450c17 causes severe 17α-hydroxylase deficiency
95. Point mutation Arg 440 to His in cytochrome P450c17 causes severe 17α-hydroxylase deficiency
96. Glucocorticoid resistance
97. Primary aldosteronism: Diagnosis and treatment
98. Primary aldosteronism: Diagnostic approaches
99. Effectiveness and safety of laparoscopic adrenalectomy
100. Laparoscopic adrenalectomy: Lessons from 100 consecutive procedures
101. Medical treatment of low-renin aldosteronism
102. Spironolactone and amiloride in hypertensive patients with and without aldosterone excess
103. Therapeutic effect of calcium channel blockade in primary aldosteronism
104. Are calcium antagonists helpful in the management of primary aldosteronism?
105. Treatment of familial hyperaldosteronism type I: Only partial suppression of adrenocorticotropin required to correct hypertension
106. Familial hyperaldosteronism type-II: Description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene
107. A novel genetic locus for low renin hypertension: Familial hyperaldosteronism type II maps to chromosome 7 (7p22)
108. Artificial mutations in P450c11AS (aldosterone synthase) can increase enzymatic activity: A model for low-renin hypertension?
109. Genetic variation in P450c11AS in Chilean patients with low renin hypertension
110. The aminoacid substitutions Ser288Gly and Val 320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme
111. Genetic analysis of aldosterone synthase in patients with idiopathic hyperaldosteronism
112. Primary aldosteronism: Learning from the study of familial varieties
113. A-6G variant of angiotensinogen gene and aldosterone levels in hypertensives
114. T235 of the angiotensinogen gene and blood pressure in the Chilean population